Tolperisone: Difference between revisions

	WikiDoc Resources for Tolperisone
Articles
Most recent articles on Tolperisone Most cited articles on Tolperisone Review articles on Tolperisone Articles on Tolperisone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tolperisone Images of Tolperisone Photos of Tolperisone Podcasts & MP3s on Tolperisone Videos on Tolperisone
Evidence Based Medicine
Cochrane Collaboration on Tolperisone Bandolier on Tolperisone TRIP on Tolperisone
Clinical Trials
Ongoing Trials on Tolperisone at Clinical Trials.gov Trial results on Tolperisone Clinical Trials on Tolperisone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tolperisone NICE Guidance on Tolperisone NHS PRODIGY Guidance FDA on Tolperisone CDC on Tolperisone
Books
Books on Tolperisone
News
Tolperisone in the news Be alerted to news on Tolperisone News trends on Tolperisone
Commentary
Blogs on Tolperisone
Definitions
Definitions of Tolperisone
Patient Resources / Community
Patient resources on Tolperisone Discussion groups on Tolperisone Patient Handouts on Tolperisone Directions to Hospitals Treating Tolperisone Risk calculators and risk factors for Tolperisone
Healthcare Provider Resources
Symptoms of Tolperisone Causes & Risk Factors for Tolperisone Diagnostic studies for Tolperisone Treatment of Tolperisone
Continuing Medical Education (CME)
CME Programs on Tolperisone
International
Tolperisone en Espanol Tolperisone en Francais
Business
Tolperisone in the Marketplace Patents on Tolperisone
Experimental / Informatics
List of terms related to Tolperisone

Tolperisone
Clinical data
Trade names	Mydocalm and others
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, parenteral
ATC code	M02AX06 (WHO) M03BX04 (WHO);
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	Liver, kidney
Elimination half-life	1st phase: 2 hrs; 2nd phase: 12 hrs
Excretion	Renal
Identifiers
	IUPAC name 2-methyl-1-(4-methylphenyl)-3-(1-piperidyl)propan-1-one;
CAS Number	728-88-1 ;
PubChem CID	5511;
UNII	F5EOM0LD8E;
KEGG	D08617 ;
ChEMBL	ChEMBL1076211 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C16H23NO
Molar mass	245.36 g/mol
3D model (JSmol)	Interactive image;
	SMILES C1CCCN(C1)CC(C(C2=CC=C(C=C2)C)=O)C;
	InChI InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3 ; Key:FSKFPVLPFLJRQB-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 17:19, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tolperisone, a piperidine derivative, is a centrally acting muscle relaxant. Trade names include Biocalm, Muscodol, Mydeton, Mydocalm, Myolax, Myoxan and Viveo.

Clinical use

In Tolperisone is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.^[1]^[2]

Other possible uses include:^{[citation needed]}

Spondylosis
Spondylarthrosis
Cervical and lumbar syndromes
Arthrosis of the large joints
Obliterating atherosclerosis of the extremity vessels
Diabetic angiopathy
Thromboangiitis obliterans
Raynaud's syndrome

Contraindications and cautions

Manufacturers report that tolperisone should not be used in patients with myasthenia gravis. Only limited data are available regarding the safety in children, youths, during pregnancy and breastfeeding. It is not known whether tolperisone is excreted into mother's milk.^[1]^[2]

Side effects

Adverse effects occur in fewer than 1% of patients and include muscle weakness, headache, arterial hypotension, nausea, vomiting, dyspepsia, and dry mouth. All effects are reversible.^[1]^[2] Allergic reactions occur in fewer than 0.1% of patient and include skin rash, hives, Quincke's edema, and in some cases anaphylactic shock.^[1]^[3]^[4]^[5]

Overdose

Excitability has been noted after ingestion of high doses by children.^[1] In suicide studies of three isolated cases, it is believed that ingestion of tolperisone was the cause of death.^[6]

Interactions

Tolperisone does not have a significant potential for interactions with other pharmaceutical drugs. It cannot be excluded that combination with other centrally acting muscle relaxants, benzodiazepines or non-steroidal anti-inflammatory drugs (NSAIDs) may make a dose reduction necessary in some patients.^[1]^[2]

Mechanism of action

Tolperisone is a centrally acting muscle relaxant that acts at the reticular formation in the brain stem^[1] by blocking voltage-gated sodium and calcium channels.^[7]^[8]

Pharmacokinetics

Tolperisone is absorbed nearly completely from the gut and reaches its peak blood plasma concentration after 1.5 hours. It is extensively metabolised in the liver and kidneys. The substance is excreted via the kidneys in two phases; the first with a half-life of two hours, and the second with a half-life of 12 hours.^[1]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 Jasek, W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 5510–1. ISBN 978-3-85200-181-4.
↑ ^2.0 ^2.1 ^2.2 ^2.3 "Midocalm". Romania: InfoMedic.
↑ Ribi C, Vermeulen C, Hauser C (2003). "Anaphylactic reactions to tolperisone (Mydocalm)". Swiss Medical Weekly. 133 (25–26): 369–371. PMID 12947534.
↑ Kwaśniewski A, Korbuszewska-Gontarz B, Mika S (2003). "[Mydocalm causing anaphylaxis]". Pneumonol Alergol Pol (in Polish). 71 (5–6): 250–2. PMID 14587432. |access-date= requires |url= (help)
↑ Glück J, Rymarczyk B, Rogala B (2011). "An immediate hypersensitivity reaction caused by tolperisone hydrochloride". J Investig Allergol Clin Immunol. 21 (5): 411–2. PMID 21905508. |access-date= requires |url= (help)
↑ Sporkert, F.; Brunel, C.; Augsburger, M. P.; Mangin, P. (2012). "Fatal tolperisone poisoning: Autopsy and toxicology findings in three suicide cases". Forensic Science International. 215 (1): 101–104. doi:10.1016/j.forsciint.2011.05.025. PMID 21683537.
↑ Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005). "Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels". Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1237–1246. doi:10.1124/jpet.105.089805. PMID 16126840.
↑ Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W (2006). "A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms". European Journal of Pharmacology. 538 (1–3): 5–14. doi:10.1016/j.ejphar.2006.03.034. PMID 16650844.

External links

[Austria-Codex-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 Jasek, W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 5510–1. ISBN 978-3-85200-181-4.

[Midocalm-ro-2] 2.0 ^2.1 ^2.2 ^2.3 "Midocalm". Romania: InfoMedic.

[3] Ribi C, Vermeulen C, Hauser C (2003). "Anaphylactic reactions to tolperisone (Mydocalm)". Swiss Medical Weekly. 133 (25–26): 369–371. PMID 12947534.

[pmid14587432-4] Kwaśniewski A, Korbuszewska-Gontarz B, Mika S (2003). "[Mydocalm causing anaphylaxis]". Pneumonol Alergol Pol (in Polish). 71 (5–6): 250–2. PMID 14587432. |access-date= requires |url= (help)

[pmid21905508-5] Glück J, Rymarczyk B, Rogala B (2011). "An immediate hypersensitivity reaction caused by tolperisone hydrochloride". J Investig Allergol Clin Immunol. 21 (5): 411–2. PMID 21905508. |access-date= requires |url= (help)

[6] Sporkert, F.; Brunel, C.; Augsburger, M. P.; Mangin, P. (2012). "Fatal tolperisone poisoning: Autopsy and toxicology findings in three suicide cases". Forensic Science International. 215 (1): 101–104. doi:10.1016/j.forsciint.2011.05.025. PMID 21683537.

[7] Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005). "Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels". Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1237–1246. doi:10.1124/jpet.105.089805. PMID 16126840.

[8] Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W (2006). "A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms". European Journal of Pharmacology. 538 (1–3): 5–14. doi:10.1016/j.ejphar.2006.03.034. PMID 16650844.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

@@ Line 1: / Line 1: @@
-{{Drugbox|
-|IUPAC_name = 2-methyl-1-(4-methylphenyl)-3-(1-piperidyl)propan-1-one
-| image=Tolperisone.svg
-| width = 120
-| CAS_number=728-88-1
-| ATC_prefix=M03
-| ATC_suffix=BX04
-| ATC_supplemental=
-| PubChem=5511
-| DrugBank=
-| C = 16 | H = 23 | N = 1 | O = 1
-| molecular_weight = 245.36 g/mol
-| bioavailability=
-| metabolism =
-| elimination_half-life=
-| excretion =
-| pregnancy_category =
-| legal_status =
-| routes_of_administration=
-}}
-'''Tolperisone''', a [[piperidine]] derivative, is a centrally acting [[muscle relaxant]]. Brand names include '''Mydocalm''' and '''Mydeton'''.
 {{Drugbox
 | Verifiedfields = changed
@@ Line 26: / Line 4: @@
 | verifiedrevid = 451425253
 | IUPAC_name = 2-methyl-1-(4-methylphenyl)-3-(1-piperidyl)propan-1-one
-| image = Tolperisone-2d-skeletal.png
+| image =Tolperisone-2d-skeletal.png
 | width = 150
@@ Line 67: / Line 45: @@
 | StdInChIKey = FSKFPVLPFLJRQB-UHFFFAOYSA-N
 }}
 __Notoc__
 {{SI}}
 {{CMG}}
 ==Overview==
 '''Tolperisone''', a [[piperidine]] derivative, is a centrally acting [[muscle relaxant]]. Trade names include '''Biocalm''', '''Muscodol''', '''Mydeton''', '''Mydocalm''', '''Myolax''', '''Myoxan''' and '''Viveo'''.
@@ Line 110: / Line 85: @@
 == See also ==
-* Chemically and mechanistically related drugs: [[eperisone]], [[inaperisone]], [[lanperisone]], [[silperisone]]
+* Chemically and mechanistically related drugs: [[eperisone]]
 == References ==
@@ Line 116: / Line 91: @@
 == External links ==
-* {{ cite web | url = http://lib.bioinfo.pl/meid:189350 | title = Tolperisone: Administration & Dosage - Papers | publisher = BioInfo | location = Poland }}{{dead link|date=December 2013}}
-{{Muscle relaxants}}
+[[Category:Drug]]
 [[Category:Piperidines]]
 [[Category:Muscle relaxants]]
-[[Category:Aromatic ketones]]